Viking Therapeutics, Inc. (VKTX) Plans $200M Equity, $200M Convertible Notes Offerings

Viking Therapeutics plans public offerings of $200M common stock and $200M convertible senior notes due 2032, each with a 30-day underwriters’ option for up to $30M more, subject to market and other conditions.Material DetailsContext by AI AnalystThis is a financing move to fund late-stage obesity…